Natixis cut its holdings in Hill-Rom Holdings, Inc. (NYSE:HRC) by 64.4% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 57,783 shares of the medical technology company’s stock after selling 104,591 shares during the period. Natixis’ holdings in Hill-Rom were worth $6,045,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System lifted its holdings in Hill-Rom by 0.6% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 85,337 shares of the medical technology company’s stock valued at $9,034,000 after purchasing an additional 510 shares in the last quarter. BB&T Securities LLC purchased a new position in Hill-Rom in the 2nd quarter valued at about $322,000. Martingale Asset Management L P lifted its holdings in Hill-Rom by 5.4% in the 1st quarter. Martingale Asset Management L P now owns 496,990 shares of the medical technology company’s stock valued at $52,612,000 after purchasing an additional 25,415 shares in the last quarter. Parametric Portfolio Associates LLC lifted its holdings in Hill-Rom by 10.5% in the 1st quarter. Parametric Portfolio Associates LLC now owns 149,080 shares of the medical technology company’s stock valued at $15,782,000 after purchasing an additional 14,223 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC lifted its holdings in Hill-Rom by 142.2% in the 2nd quarter. Campbell & CO Investment Adviser LLC now owns 5,812 shares of the medical technology company’s stock valued at $608,000 after purchasing an additional 3,412 shares in the last quarter. Institutional investors and hedge funds own 82.74% of the company’s stock.
A number of research analysts have issued reports on the stock. Barclays upped their target price on shares of Hill-Rom from $108.00 to $116.00 and gave the company an “equal weight” rating in a report on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and issued a $125.00 target price on shares of Hill-Rom in a report on Tuesday, August 6th. KeyCorp upped their target price on shares of Hill-Rom from $114.00 to $125.00 and gave the company an “overweight” rating in a report on Monday, August 5th. ValuEngine lowered shares of Hill-Rom from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research upgraded shares of Hill-Rom from a “hold” rating to a “buy” rating and set a $103.00 target price on the stock in a report on Thursday, June 6th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $112.43.
Shares of HRC stock traded down $0.09 during trading hours on Thursday, hitting $106.04. 6,308 shares of the company were exchanged, compared to its average volume of 456,299. The firm has a market cap of $7.14 billion, a PE ratio of 22.26, a PEG ratio of 2.09 and a beta of 0.87. Hill-Rom Holdings, Inc. has a 1 year low of $81.82 and a 1 year high of $109.18. The company has a quick ratio of 1.14, a current ratio of 1.51 and a debt-to-equity ratio of 1.12. The firm has a fifty day moving average of $105.87 and a 200 day moving average of $103.45.
Hill-Rom (NYSE:HRC) last announced its quarterly earnings data on Friday, August 2nd. The medical technology company reported $1.23 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.21 by $0.02. The business had revenue of $726.80 million for the quarter, compared to analyst estimates of $718.08 million. Hill-Rom had a net margin of 7.45% and a return on equity of 21.26%. The company’s revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm posted $1.15 EPS. Analysts expect that Hill-Rom Holdings, Inc. will post 5.05 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Friday, September 20th will be issued a dividend of $0.21 per share. The ex-dividend date is Thursday, September 19th. This represents a $0.84 annualized dividend and a dividend yield of 0.79%. Hill-Rom’s payout ratio is currently 17.68%.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Read More: Quantitative Easing
Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.